Who owns Cytomx Therapeutics?
- Ticker: CTMX
- CUSIP Number: 23284f105
Tip: Access positions for across all investors
Analyze quarterly positions in Cytomx Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Cytomx Therapeutics stock
Who bought or sold Cytomx Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Tang Capital Management | 7.8M | $9.2M | 0% | Sep 2024 |
|
| Henderson Group | 6.3M | $7.7M | 100% | Jun 2024 |
|
| BVF | 5.2M | $6.2M | 0% | Sep 2024 |
|
| Vanguard Group | 4.9M | $6.0M | 1% | Jun 2024 |
|
| Acadian Asset Management | 3.1M | $3.7M | 14% | Sep 2024 |
|
| Assenagon Asset Management | 1.6M | $1.9M | 33% | Sep 2024 |
|
| Jacobs Levy Equity Management | 1.5M | $1.8M | 1% | Sep 2024 |
|
| Laurion Capital Management | 1.2M | $1.5M | -18% | Sep 2024 |
|
| Congress Park Capital | 1.2M | $1.4M | 5% | Sep 2024 |
|
| Schonfeld Strategic Advisors | 1.2M | $1.4M | -12% | Sep 2024 |
|
| BlackRock | 1.2M | $1.4M | 100% | Sep 2024 |
|
| Superstring Capital Management | 1.2M | $1.4M | 69% | Jun 2024 |
|
| BlackRock | 1.1M | $1.4M | 1% | Jun 2024 |
|
| Renaissance Technologies | 1.0M | $1.2M | -14% | Sep 2024 |
|
| Geode Capital Management | 804k | $948k | 4% | Sep 2024 |
|
| Two Sigma Investments | 662k | $808k | 161% | Jun 2024 |
|
| Sei Investments | 488k | $576k | 100% | Sep 2024 |
|
| Woodline Partners | 394k | $465k | 100% | Sep 2024 |
|
| Bridgeway Capital Management | 369k | $450k | -17% | Jun 2024 |
|
| Citadel Advisors | 328k | $388k | -35% | Sep 2024 |
|
| Ghost Tree Capital | 300k | $366k | -50% | Jun 2024 |
|
| Connor, Clark & Lunn Investment Management | 281k | $331k | 10% | Sep 2024 |
|
| State Street Corporation | 264k | $322k | -1% | Jun 2024 |
|
| BBK Capital Partners | 246k | $290k | -5% | Sep 2024 |
|
| Toroso Investments | 246k | $290k | -5% | Sep 2024 |
|
| Bank of New York Mellon | 242k | $286k | 0% | Sep 2024 |
|
| Candriam Luxembourg S.C.A. | 210k | $257k | 100% | Jun 2024 |
|
| Squarepoint Ops | 199k | $243k | -23% | Jun 2024 |
|
| Morgan Stanley | 189k | $232k | -78% | Jun 2024 |
|
| Two Sigma Advisers | 158k | $193k | 8% | Jun 2024 |
|
| Northern Trust | 130k | $153k | -3% | Sep 2024 |
|
| Goldman Sachs Group | 109k | $133k | -63% | Jun 2024 |
|
| Creative Planning | 107k | $126k | 0% | Sep 2024 |
|
| Virtu Financial | 89k | $104k | 100% | Sep 2024 |
|
| Forefront Analytics | 60k | $71k | -7% | Sep 2024 |
|
| Qube Research & Technologies | 55k | $67k | -59% | Jun 2024 |
|
| Susquehanna Fundamental Investments | 54k | $66k | -4% | Jun 2024 |
|
| Commonwealth Equity Services | 54k | $64k | 0% | Sep 2024 |
|
| Private Advisor | 52k | $62k | 0% | Sep 2024 |
|
| Stifel Financial | 47k | $58k | 100% | Jun 2024 |
|
| Russell Investments | 43k | $52k | 0% | Jun 2024 |
|
| CornerCap Investment Counsel | 42k | $49k | -49% | Sep 2024 |
|
| LPL Financial | 38k | $45k | 6% | Sep 2024 |
|
| Invesco | 38k | $44k | 62% | Sep 2024 |
|
| Us Bancorp | 34k | $40k | 100% | Sep 2024 |
|
| AJOVista | 33k | $39k | 100% | Sep 2024 |
|
| Jane Street | 27k | $32k | -66% | Sep 2024 |
|
| Hrt Financial | 27k | $31k | 100% | Sep 2024 |
|
| Charles Schwab Investment Management | 25k | $29k | 0% | Sep 2024 |
|
| Cubist Systematic Strategies | 25k | $29k | -70% | Sep 2024 |
|
| Bank of America Corporation | 21k | $24k | 258% | Sep 2024 |
|
| Taddei, Ludwig & Associates | 17k | $20k | 0% | Sep 2024 |
|
| Tower Research Capital | 17k | $21k | 100% | Jun 2024 |
|
| Nierenberg Investment Management Company | 13k | $15k | 100% | Jun 2024 |
|
| IPG Investment Advisors | 13k | $15k | 0% | Jun 2024 |
|
| EP Wealth Advisors | 10k | $12k | 100% | Sep 2024 |
|
| Susquehanna International | 10k | $12k | -82% | Sep 2024 |
|
| Peregrine Asset Advisers | 10k | $12k | 100% | Sep 2024 |
|
| Ikarian Capital | 8.9k | $11k | 0% | Sep 2024 |
|
| Lazard Asset Management | 8.8k | $10k | -52% | Sep 2024 |
|
| Group One Trading | 4.9k | $5.8k | -71% | Sep 2024 |
|
| Advisor Group Holdings | 900.00 | $1.1k | 100% | Sep 2024 |
|
| Bollard | 712.00 | $1.0k | 0% | Sep 2024 |
|
| Jpmorgan Chase & Co | 281.00 | $332.001500 | 0% | Sep 2024 |
|
| Raleigh Capital Management | 250.00 | $295.000000 | 0% | Sep 2024 |
|
| Bnp Paribas Arbitrage, Snc | 194.00 | $228.997600 | 149% | Sep 2024 |
|
| Federated Investors | 117.00 | $138.001500 | 0% | Sep 2024 |
|
Who sold out of Cytomx Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Millennium Management | Jun 2024 | 1.8M | $2.3M |
| Sio Capital Management | Mar 2024 | 1.6M | $3.5M |
| GSA Capital Partners | Jun 2024 | 229k | $279k |
| XTX Topco | Jun 2024 | 61k | $74k |
| OMERS Administration Corporation | Mar 2024 | 35k | $77k |
| Balyasny Asset Management | Mar 2024 | 32k | $70k |
| LMR Partners | Jun 2024 | 15k | $18k |
| ExodusPoint Capital Management | Mar 2024 | 11k | $24k |
| Simplex Trading | Jun 2024 | 3.9k | $4.0k |
| Whittier Trust | Jun 2024 | 2.2k | $2.7k |
| Rhumbline Advisers | Jun 2024 | 1.3k | $1.6k |
| Macquarie Group | Mar 2024 | 1.1k | $2.041200 |
| Royal Bank of Canada | Jun 2024 | 248.00 | $0 |